First Time Loading...

Invitae Corp

Watchlist Manager
Invitae Corp Logo
Invitae Corp
Price: 0.64 USD -3.03%
Updated: Sep 26, 2023

Intrinsic Value

Intrinsic Value History
Invitae Corp

Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.

This feature available only with
Unlimited Plan

Sign up to access Invitae Corp's intrinsic value history.

No restrictions, no limits.
All stocks, all tools.

Spot Contrarian Opportunities

Look for stocks that have been historically overvalued but are now trading below their intrinsic value.

Easily Identify Value Traps

Avoid stocks that are always undervalued and never reach their intrinsic value.

Find Strong Rebounds

Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.

Fundamental Analysis


Balance Sheet Decomposition
Invitae Corp

Current Assets 451m
Cash & Short-Term Investments 325m
Receivables 85.6m
Other Current Assets 40.5m
Non-Current Assets 1.1B
PP&E 167m
Intangibles 874m
Other Non-Current Assets 31.1m
Current Liabilities 152m
Accounts Payable 23.1m
Accrued Liabilities 115m
Other Current Liabilities 13.6m
Non-Current Liabilities 1.6B
Long-Term Debt 1.4B
Other Non-Current Liabilities 150m
Fundamental Scores

NVTA Profitability Score
Profitability Due Diligence

Invitae Corp's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROIC is Increasing
Positive Gross Profit
Positive Revenue Growth Forecast

Invitae Corp's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

NVTA Solvency Score
Solvency Due Diligence

Invitae Corp's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Short-Term Solvency
Long-Term Solvency
Positive Net Debt

Invitae Corp's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NVTA Price Targets Summary
Invitae Corp

Wall Street analysts forecast NVTA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NVTA is 1.73 USD with a low forecast of 0.51 USD and a high forecast of 4.2 USD.

Price Target
0.51 USD
21% Downside
Price Target
1.73 USD
171% Upside
Price Target
4.2 USD
556% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape


NVTA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

NVTA Return Decomposition
Main factors of price return

What is price return decomposition?

NVTA Price
Invitae Corp

1M 1M
6M 6M
1Y 1Y
3Y 3Y
5Y 5Y
10Y 10Y
Annual Price Range
52w Low
52w High
Price Metrics
Average Annual Return 28.76%
Standard Deviation of Annual Returns 102.8%
Max Drawdown -99%
Shares Statistics
Market Capitalization 179m USD
Shares Outstanding 260 675 008
Percentage of Shares Shorted 16.2%


Last Video News
Invitae Corp

Other Videos

Company Profile

Invitae Corp Logo
Invitae Corp


United States of America


Health Care

Market Cap

179m USD

Dividend Yield



Invitae Corp. engages in the provision of genetic information into mainstream medical practice. The company is headquartered in San Francisco, California and currently employs 3,000 full-time employees. The company went IPO on 2015-02-12. The firm is engaged in delivering genetic testing services that support a lifetime of patient care from inherited disease diagnoses, to family planning, to proactive health screening to personalized diagnosis, treatment and monitoring of cancer. These tests are delivered through a platform that serves patients, healthcare providers, biopharma companies and other partners, thereby capturing the potential of genetics and helping to expand its use across the healthcare continuum. The company offers Invitae Digital Health, a connected digital health platform that informs health decisions through actionable genomic insights for patients and clinicians. The firm offers genetic testing across multiple clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, personalized oncology, metabolic conditions, and rare diseases.


San Francisco
1400 16th St




3 000


Pres, CEO & Director
Mr. Kenneth D. Knight
Chief Financial Officer
Ms. Yafei Wen
Gen. Counsel, Chief Compliance Officer & Sec.
Mr. Thomas R. Brida
Chief Medical Officer
Dr. Robert L. Nussbaum M.D.
Chief Sustainability Officer
Ms. Shelly D. Guyer
Chief Accounting Officer & Principal Accounting Officer
Mr. Robert F. Werner
Show More
Head of Investor Relations and Capital Markets
Ms. Hoki Luk
Chief Policy Officer
Mr. Lee Bendekgey J.D.
Head of Talent
Glenn Medalle
Chief Talent Officer
Ms. Desarie French
Show Less

See Also

Other Stocks